Table 1.
MRT Parameters Used in Cancer Models.
| Animal | Cancer Type | Number of Arrays | Microbeam | Peak-dose (Gy) | Valley-dose (Gy) | Evaluated Criteria | |
|---|---|---|---|---|---|---|---|
| Width (µm) | Spacing (µm) | ||||||
| Rat [1] | Gliosarcoma (9L) | 1 & 2 | 50 | 200 | 400 entrance dose; 350 @1cm depth |
12.5 @1cm depth | Animal survival, tumour growth, tumour vasculature, and cell proliferation |
| Rat [2] | Gliosarcoma (9L) | 2 | 50 | 200 | 480 entrance dose; 418 @1cm depth |
18.6 @1cm depth | Animal survival, cell cycle, and DNA distribution patterns |
| Rat [3] | Gliosarcoma (9L) | 2 | 50 | 200 | 400 entrance dose; 350 @1cm depth |
12.5 @1cm depth | Tumour vasculature and tumour oxygenation |
| Rat [4] | Gliosarcoma (9L) | 1 | 50 | 200 | 400 dose @tumour (i.e., @7mm depth) |
18 dose @tumour (i.e., @7mm depth) | Animal survival and Transcriptomics |
| Rat [5] | Gliosarcoma (9L) | 1 | 50 | 200 | 400 dose @tumour (i.e., @7mm depth) |
8 dose @tumour (i.e., @7mm depth) | Tumour growth, transcriptomics, and histopathology |
| Rat [6] | Gliosarcoma (9L) | 1 | 50 | 200 | 400 dose @tumour (i.e., @7mm depth) |
17.4 dose @tumour (i.e., @7mm depth) | Animal survival, tumour growth, cell proliferation, and gene expression |
| 200 dose @tumour (i.e., @7mm depth) | 8.7 dose @tumour (i.e., @7mm depth) | ||||||
| Rat [7] | Glioma (F98) | 2 | 50 | 200 | 241.4 entrance dose | 10.5 @9mm depth | Tumour vasculature and tumour oxygenation |
| Mouse [8] | Mammary (EMT6.5/67NR) | 1 | 25 | 200 | 560 entrance dose | 8.5 @centre of brain | Animal survival, DNA damage, cell proliferation, and apoptosis |
| 800 entrance dose | 12 @centre of brain | ||||||
| 2 | 280 entrance dose | 8.5 @centre of brain | |||||
| 560 entrance dose | 17 @centre of brain | ||||||
| Rat [9] | Gliosarcoma (9L) | 1 | 27 | 50 | 150 entrance dose; 108 @centre of brain |
20 @centre of brain | Animal survival and histopathology |
| 250 entrance dose; 179 @centre of brain |
34 @centre of brain | ||||||
| 300 entrance dose; 215 @centre of brain |
40 @centre of brain | ||||||
| 75 | 250 entrance dose; 179 @centre of brain |
17 @centre of brain | |||||
| 300 entrance dose; 215 @centre of brain |
20 @centre of brain | ||||||
| 500 entrance dose; 359 @centre of brain |
33 @centre of brain | ||||||
| 100 | 500 entrance dose; 359 @centre of brain |
19 @centre of brain | |||||
| Mouse [10] | Mammary (EMT6.5) | 1 | 90 | 300 | 800 dose @tumour | 16 dose @tumour | Tumour ablation |
| 890 dose @tumour | 18 dose @tumour | ||||||
| 970 dose @tumour | 19 dose @tumour |
||||||
| 1740 dose @tumour | 35 dose @tumour | ||||||
| 1820 dose @tumour | 36 dose @tumour | ||||||
| 1900 dose @tumour | 38 dose @tumour | ||||||
| 2 | 90 | 300 | 410 dose @tumour | 16 dose @tumour | |||
| 520 dose @tumour | 21 dose @tumour | ||||||
| 650 dose @tumour | 26 dose @tumour | ||||||
| Rat [11] | Glioma (C6) | 1 | 25 | 200 | 17.5, 35, 70, 350 entrance dose | 0.51, 1.03, 2, 10.3 | Bystander effects in-vivo by clonogenic cell survival |
| Rat [12] | Glioma (C6) | 1 | 25 | 200 | 35, 70, 350 entrance dose | NR | DNA damage |
| Rat [13] | Glioma (F98) | 1 | 25 | 200 | 20, 200 entrance dose | NR | Bystander effects in-vivo by clonogenic cell survival and cellular calcium fluxes |
| Mouse nude [14] | Glioma (F98) | 50 | 400 | 22, 110 entrance dose | 0.5, 2.5 | Bystander effects in-vivo by clonogenic cell survival and cellular calcium fluxes | |
| Mouse [15] | Mammary (4T1) | 1 | 50 | 200 | 150 @5 mm depth | 7.5 in a 10 mm solid water phantom |
Tumour growth, tumour vasculature, and tumour hypoxia |
| Mouse [16] | Mammary (EMT6.5) | 1 | 25 | 200 | 112, 560 | NR | Immune response by gene expression and histopathology |
| Rat [17] | Gliosarcoma (9L) | 1 | 50 | 200 | 400 entrance dose | NR | Tumour vasculature, and tumour hypoxia |
| Rat [18] | Gliosarcoma (9L) | 1 | 25 | 100 | 625 entrance dose | NR | Animal survival, tumour growth, and histopathology |
| Mouse [19] | Squamous cell carcinoma (SCCVII) | 1 | 35 | 200 | 442, 625, 884 entrance dose | NR | Animal survival, tumour growth, and tumour ablation |
| 70 | 200 | 442 entrance dose | |||||
| Rat [20] | Glioma (C6) | 2 | 25 | 200 | 350 entrance dose | NR | Optic nerve damage by histopathology |
| Mouse [21] | Melanoma (B16F10) | 1 | 50 | 200 | 407.6 dose @tumour | 6.2 dose @tumour | Tumour growth, tumour vasculature, cell proliferation, cell senescence, and immune response |
| Rat [22] | Gliosarcoma (9L) | 1 | 25 | 200 | 625 entrance dose | 12.1 dose @tumour | Animal survival, tumour growth, and histopathology |
| 100 | 625 entrance dose | 36 dose @tumour | |||||
| Rat [23] | Gliosarcoma (9L) | 1 | 25 | 200 | 625 entrance dose | NR | Animal survival, tumour growth, and histopathology |
| Mouse [24] | Mammary (EMT6.5) | 1 | 25 | 200 | 560 entrance dose | 11 | Biochemical changes by synchrotron Fourier-transform infrared microspectroscopy |
| Rat [25] | Glioma (C6, F98) | 2 | 25 | 211 | 350 entrance dose | NR | Animal survival and object recognition |
| Rat [26] | Glioma (F98) | 2 | 28 | 400 | 350 | 18 dose @ tumour | Animal survival and cognitive dysfunction |
| Mouse nude [27] | Gliosarcoma (9L) | 1 | 25 | 211 | 500 entrance dose | 24 (cross-fired) | Animal survival, tumour growth, and tumour vasculature |
| Rat [28] | Gliosarcoma (9L) | 2 | 25 | 211 | 860 entrance dose | 18 @1cm depth | Animal survival and histopathology |
| 50 | 480 entrance dose | ||||||
| 75 | 320 entrance dose | ||||||
| Rat [29] | Gliosarcoma (9L) | 3 | 50 | 211 | 400, 360 (+24h), 400 (+48h) entrance dose | 15 | Animal survival and histopathology |
| Rat [30] | Gliosarcoma (9L) | 1 | 27 | 211 | 625 entrance dose | NR | Animal survival, histopathology, and immune response |
| Mouse [31] | Mammary (EMT6.5) | 1 | 25 | 200 | 560 | 11 | Transcriptomics |
| Mouse nude [32] | Glioma (U251) | 1 | 100 | 500 | 124 | 4.8 | Tumour growth, histopathology, and apoptosis |
| 2 | 20 | 100 | 111 | 8.2 | |||
| 100 | 500 | 124 | 9.6 | ||||
| Mouse [33] | Mammary (EMT6.5) | 1 | 25 | 200 | 112, 560 | NR | Immune response |
NR: Not-Reported.